Drugs / PL2200
PL2200
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01646814 | Sep 2012 → Jun 2013 | peptic ulcer disease | PLx Pharma | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04811625 | Apr → Sep 2021 | — | PLx Pharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PL2200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01646814 ↗ |
| Known as | phospholipid-aspirin | “Phospholipid-aspirin liquid filled capsules (PL-ASA) are a novel FDA-approved immediate-release formulation designed to reduce gastrointestinal (GI) injury by limiting direct...” PMID 36036856 ↗ Aug 2022 |
| Known as | PL-ASA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04811625 ↗ |